NeuroXess aims for human trials

NeuroXess, a Chinese company active in the field of brain-computer interfaces (BCI), is rapidly advancing towards the human trial phase. This development is fueled by a mix of government support and strong investor interest, allowing the company to accelerate its time to market.

Brain-computer interfaces represent a rapidly expanding field of research, with the potential to improve the quality of life for people with motor disabilities, restoring some functionality lost due to injury or illness. BCI technology could also open new frontiers in the field of robotics and human-machine interaction.

For those evaluating on-premise deployment of systems for analyzing data generated by BCIs, there are trade-offs between initial costs and data control. AI-RADAR offers analytical frameworks on /llm-onpremise to evaluate these options.